Anxiety disorder
Conditions
Interventions
Experimental Group 1:Biofeedback combined with microcurrent stimulation
Experimental Group 2:Biofeedback combined with microcurrent stimulation
Experimental Group 3:Pure microcurrent stimulation intervention
Experimental Group 4:Pure microcurrent stimulation intervention
Control group:Sham biofeedback therapy combined with sham microcurrent stimulation intervention
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with an anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), or anxiety with depression where anxiety is the primary diagnosis; 2. Hamilton Anxiety Scale (HAMA) score >=22; 3. Hamilton Depression Rating Scale (HAMD-17) score <=17; 4. Age range 18-65 years; 5. First-time patients who have not used medication or have had poor response to medication; 6. Not participating in other physical therapies outside of this experiment; 7. Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects meet the DSM-V criteria, excluding anxiety disorders as the primary diagnosis (i.e., schizophrenia, depression, mood disorders, psychosis, anorexia nervosa); 2. History of skin lesions, eczema, or other skin conditions affecting the skin behind the ears (e.g., psoriasis); 3. History of suicide attempts within the past year, or currently at high risk of suicide, or patients with a score of =2 on item 3 of the Hamilton Depression Rating Scale (HAMD-17); 4. Previously diagnosed with HIV infection or AIDS; 5. History of stroke or severe head injury (defined as head injury requiring craniotomy or intubation); 6. Presence of permanently implanted battery-powered medical devices or stimulators (e.g., pacemaker, implantable defibrillator, deep brain stimulator, vagus nerve stimulator, etc.); 7. Women who are pregnant, breastfeeding, or planning to become pregnant; 8. History of epilepsy; 9. History of migraine with aura; 10. History of head injury requiring intensive care or neurosurgery; 11. History of cognitive impairment; 12. History of malignant tumors in the past year or presence of malignant tumors (excluding basal cell carcinoma, squamous cell carcinoma, and carcinoma in situ) diagnosed with myelofibrosis or myelodysplastic syndrome; 13. Concurrent use of drugs that interact with or are explicitly contraindicated for the study device; 14. Use of drugs that may induce seizures within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Rating Scale (HAMA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Pittsburgh Sleep Quality Index;Hamilton Depression Rating Scale; | — |
Countries
China
Contacts
Public ContactMengqian li
The first affiliated hostipal of nanchang university
Outcome results
None listed